Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Rating) in a research note released on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Accelerate Diagnostics Stock Performance

NASDAQ:AXDX opened at $0.48 on Wednesday. The company has a 50-day moving average of $0.62 and a 200-day moving average of $1.01. Accelerate Diagnostics has a twelve month low of $0.45 and a twelve month high of $3.74.

Insider Buying and Selling

In other Accelerate Diagnostics news, CFO Steven Reichling sold 62,778 shares of the company’s stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $0.47, for a total value of $29,505.66. Following the transaction, the chief financial officer now owns 137,640 shares of the company’s stock, valued at $64,690.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Accelerate Diagnostics news, CEO Jack Phillips sold 155,635 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $0.47, for a total transaction of $73,148.45. Following the completion of the sale, the chief executive officer now directly owns 463,823 shares of the company’s stock, valued at $217,996.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Steven Reichling sold 62,778 shares of the firm’s stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $0.47, for a total transaction of $29,505.66. Following the completion of the transaction, the chief financial officer now owns 137,640 shares of the company’s stock, valued at $64,690.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 290,535 shares of company stock worth $142,098. Corporate insiders own 42.20% of the company’s stock.

Institutional Investors Weigh In On Accelerate Diagnostics

Several hedge funds have recently made changes to their positions in the company. Griffin Asset Management Inc. grew its position in Accelerate Diagnostics by 17.3% during the 4th quarter. Griffin Asset Management Inc. now owns 8,569,742 shares of the medical research company’s stock worth $6,050,000 after purchasing an additional 1,266,786 shares in the last quarter. Vanguard Group Inc. raised its position in Accelerate Diagnostics by 22.6% during the third quarter. Vanguard Group Inc. now owns 2,825,643 shares of the medical research company’s stock valued at $4,295,000 after buying an additional 520,656 shares during the period. Baird Financial Group Inc. lifted its stake in Accelerate Diagnostics by 15.5% in the 1st quarter. Baird Financial Group Inc. now owns 1,741,547 shares of the medical research company’s stock worth $2,508,000 after acquiring an additional 233,478 shares in the last quarter. State Street Corp lifted its stake in Accelerate Diagnostics by 12.9% in the 1st quarter. State Street Corp now owns 1,234,706 shares of the medical research company’s stock worth $1,778,000 after acquiring an additional 140,883 shares in the last quarter. Finally, Cannell & Co. boosted its position in Accelerate Diagnostics by 3.2% during the 3rd quarter. Cannell & Co. now owns 1,121,919 shares of the medical research company’s stock worth $1,705,000 after acquiring an additional 35,000 shares during the period. Hedge funds and other institutional investors own 33.14% of the company’s stock.

About Accelerate Diagnostics

(Get Rating)

Accelerate Diagnostics, Inc is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.